Overall, B-ALL with KMT2A mutations is associated with a poorer prognosis, a study examining tumor cell surface antigen expression in patients with KMT2A mutations revealed that KMT2A Ar+ cells exhibited heightened expression of CD45, CD38, and CD58 (57), indicating that CD58 may serve as a significant prognostic marker for B-ALL. This evidence concerns the gene CD58 and precursor B-cell acute lymphoblastic leukemia.